An interventional study of Ultra-high-caloric fatty diet and Placebo in Amyotrophic Lateral Sclerosis, sponsored by University of Ulm. Active, not recruiting at 23 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University of Ulm · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany — 17 open to participants now, 26 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · Germany.
Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, this one is the 14th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2024, is one of 6 with no phase, reaches primary completion later than 18 of the 25 other live ones, and was the 62nd registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →17 of the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany are open now. Recruiting first, the newest first:
Ambulanzpartner Soziotechnologie APST GmbH · Sites in Germany
Trace Neuroscience, Inc. · Sites in Germany, Netherlands, United Kingdom
Ages 18–75
Eli Lilly and Company · Sites in Germany, Belgium, Canada and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Germany, Belgium, Canada and 2 more countries
Ages 18–80
Leal Therapeutics, Inc · Sites in Germany, Italy, Netherlands and 1 more country
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 29 · Phase 3 25
First in 2003; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 399 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 219 across the 63 interventional studies, 200 across the 13 observational. Of the 48 that completed or were terminated, 23 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 76 have an industry lead sponsor. The 10 most frequent:
University of Ulm is the lead sponsor of 145 studies on the registry; 27 are open to participants now.
University of Ulm has 7 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Amyotrophic Lateral Sclerosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07142291PhenoNet, Inc.PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | 2027-03 |
| NCT07100119Eli Lilly and CompanyA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | 2027-08 |
| NCT06605612LMU KlinikumDevelopment and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders | 2027-08-01 |
| NCT07674667Trace Neuroscience, Inc.FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).
ALS is a fatal neurodegenerative disease, leading to progressive paralysis of voluntarily innervated muscles and to death caused by respiratory failure after a mean disease duration of 2-4 years.The proposed study aims at improving survival of ALS patients by targeting metabolic parameters. ALS patients feature an intrinsic hypermetabolism as signified by an increased resting energy expenditure, which significantly contributes to progressive weight loss and cachexia. The extent of weight loss is an independent prognostic factor for survival in ALS. It has been shown that survival of ALS mice can be prolonged by applying a high-caloric nutrition. Furthermore, ALS patients feature distinct alterations of lipid metabolism, and various studies suggest a protective effect of high triglyceride serum levels.
In the precursor-study LIPCAL-ALS-I, a randomized, placebo-controlled, multicenter trial, evaluating the effects of a high-caloric fatty diet (HCFD), the primary endpoint (survival in the whole study population) was missed. However, post-hoc analysis revealed showed that HCFD (1) increased survival and reduced weight loss in normal to fast-progressing patients (patients with a functional decline measured by ALS Functional Rating Scale Revised) above the median at baseline; p=0.02), (2) slowed down functional decline (measured by Amyotrophic Lateral Sclerosis Functional Rating Scale Revised) in the whole study population (p\<0.0125), and (3) lowered neurofilament light chain (NfL) serum levels as a prognostic biomarker in the whole study population (p=0.0225).
Therefore, this study aims at prolonging survival in ALS patients by applying 1.5-fold dosage of the same intervention as in LIPCAL-ALS I in a larger number of patients, excluding patients with slow disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ultra-high-caloric, high-fat, fluid nutritional supplement oral intake of 4 times 35 ml per day in addition to normal food intake, corresponding to +630 kcal and +70g fat per day
Dietary Supplement: Ultra-high-caloric fatty diet
placebo, fluid nutritional supplement oral intake of 4 times 35 ml per day in addition to normal food intake, corresponding to +50 kcal and +3,5g fat per day
Other: Placebo
100% fat (70g), saturated fatty acids 7,5g, monounsaturated fatty acids 42,6g, polyunsaturated fatty acids 19,9g, long-chain fatty acids 100%, ratio omega-6 to omega-3 fatty acids 5:1, protein 0g, carbohydrates 0g, fiber 0g
\<5% fat (\<3,5g), protein 0g, carbohydrates 0g, fiber 0g
Survival
Time from date of randomization until date of death, tracheostomy, or permanent continous ventilation (\>22 hours per day)
Time frame: 18 months
Amyotrophic Lateral Sclerosis Functional Rating Scale Revised
Change per month of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised
Time frame: 18 months
Rasch Overall Amyotrophic Lateral Sclerosis Disability Scale
Change per month of Rasch Overall Amyotrophic Lateral Sclerosis Disability Scale
Time frame: 18 months
Individual Quality of Life
Change of Euro Quality of Life 5D 5L (EQ-5D-5L) compared to baseline
Time frame: 18 months
Slow vital capacity
Change of slow vital capacity compared to baseline
Time frame: 18 months
Survival
Time from date of randomization until date of death, tracheostomy, or permanent continous ventilation (\>22 hours per day)
Time frame: 6 months
Survival
Time from date of randomization until date of death, tracheostomy, or permanent continous ventilation (\>22 hours per day)
Time frame: 12 months
Time to death
Time from date of randomization until date of death
Time frame: 18 months
Time to tracheostomy
Time from date of randomization until date of tracheostomy
Time frame: 18 months
Time to permanent continous ventilator dependence
Time from date of randomization to permanent continous ventilator dependence (\>22 hours per day)
Time frame: 18 month
Ventilation assistance-free survival
Time from date of randomization until implementation of mechanical ventilation
Time frame: 18 months
Body Mass Index
Change of body mass index compared to baseline
Time frame: 18 months
Council of Nutrition Appetite Questionnaire
Change of Council of Nutrition Appetite Questionnaire sum score compared to baseline
Time frame: 18 months
Eating Habits
Change of Ulm Nutrition Questionnaire compared to baseline; qualitative changes on a descriptional level (the questionnaire has no sum score); the score is meant to detect changes of eating habits and has been used in the precursor study LIPCAL-ALS I (see doi: 10.1002/ana.25661).
Time frame: 18 months
Neurofilament light chain
Change of neurofilament light chain serum levels compared to baseline
Time frame: 18 months
Amyotrophic Lateral Sclerosis Functional Rating Scale Revised Prediction Model
Difference between observed and predicted decrease of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (measured as points lost per month), based on the a prediction model, which estimates disease progression based on neurofilament light chain serum baseline levels
Time frame: 18 months
Neurofilament Assess Score
Difference between observed and predicted survival based on the Neurofilament Assess Score, a score estimating survival based on the neurofilament light chain serum baseline levels
Time frame: 18 months
Microtubule-associated protein 2 in serum
change of Microtubule-associated protein 2 levels in serum compared to baseline
Time frame: 18 months
Microtubule-associated protein 2 in cerebrospinal fluid
change of microtubule-associated protein 2 levels in cerebrospinal fluid compared to baseline
Time frame: 18 months
Ubiquitin carboxy-terminal hydrolase L1 in serum
change of ubiquitin carboxy-terminal hydrolase L1 levels in serum compared to baseline
Time frame: 18 months
Ubiquitin carboxy-terminal hydrolase L1 in cerebrospinal fluid
change of ubiquitin carboxy-terminal hydrolase L1 levels in cerebrospinal fluid compared to baseline
Time frame: 18 months
Transmembrane glycoprotein NMB in serum
change of transmembrane glycoprotein NMB levels in serum compared to baseline
Time frame: 18 months
Transmembrane glycoprotein NMB in cerebrospinal fluid
change of transmembrane glycoprotein NMB levels in cerebrospinal fluid compared to baseline
Time frame: 18 months
Human cartilage glycoprotein 39 in serum
change of human cartilage glycoprotein 39 levels in serum compared to baseline
Time frame: 18 months
Human cartilage glycoprotein 39 in cerebrospinal fluid
change of human cartilage glycoprotein 39 levels in cerebrospinal fluid compared to baseline
Time frame: 18 months
SNAP-25 in serum
change of SNAP-25 levels in serum compared to baseline
Time frame: 18 months
SNAP-25 in cerebrospinal fluid
change of SNAP-25 levels in cerebrospinal fluid compared to baseline
Time frame: 18 months
Beta-synuclein in serum
change of beta-synuclein levels in serum compared to baseline
Time frame: 18 months
Beta-synuclein in cerebrospinal fluid
change of beta-synuclein levels in cerebrospinal fluid compared to baseline
Time frame: 18 months
Aquaporin-4 in serum
change of aquaporin-4 levels in serum compared to baseline
Time frame: 18 months
Aquaporin-4 in cerebrospinal fluid
change of aquaporin-4 levels in cerebrospinal fluid compared to baseline
Time frame: 18 months
Glial fibrillary acidic protein in serum
change of glial fibrillary acidic protein levels in serum compared to baseline
Time frame: 12 months
Glial fibrillary acidic protein in cerebrospinal fluid
change of glial fibrillary acidic protein levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
Soluble triggering receptor expressed on myeloid cell-1 in serum
change of soluble triggering receptor expressed on myeloid cell-1 levels in serum compared to baseline
Time frame: 12 months
Soluble triggering receptor expressed on myeloid cell-1 in cerebrospinal fluid
change of soluble triggering receptor expressed on myeloid cell-1 levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
CC-chemokine ligand 2 in serum
change of CC-chemokine ligand 2 levels in serum compared to baseline
Time frame: 12 months
CC-chemokine ligand 2 in cerebrospinal fluid
change of CC-chemokine ligand 2 levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
interleukin-1b in serum
change of interleukin-1b levels in serum compared to baseline
Time frame: 12 months
interleukin-1b in cerebrospinal fluid
change of interleukin-1b levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
interleukin-2 in serum
change of interleukin-2 levels in serum compared to baseline
Time frame: 12 months
interleukin-2 in cerebrospinal fluid
change of interleukin-2 levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
interleukin-4 in serum
change of interleukin-4 levels in serum compared to baseline
Time frame: 12 months
interleukin-4 in cerebrospinal fluid
change of interleukin-4 levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
interleukin-6 in serum
change of interleukin-6 levels in serum compared to baseline
Time frame: 12 months
interleukin-6 in cerebrospinal fluid
change of interleukin-6 levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
interleukin-10 in serum
change of interleukin-10 levels in serum compared to baseline
Time frame: 12 months
interleukin-10 in cerebrospinal fluid
change of interleukin-10 levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
interleukin-12p70 in serum
change of interleukin-12p70 levels in serum compared to baseline
Time frame: 12 months
interleukin-12p70 in cerebrospinal fluid
change of interleukin-12p70 levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
interleukin-17 in serum
change of interleukin-17 levels in serum compared to baseline
Time frame: 12 months
interleukin-17 in cerebrospinal fluid
change of interleukin-17 levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
Tumor necrosis factor alpha in serum
change of tumor necrosis factor alpha levels in serum compared to baseline
Time frame: 12 months
Tumor necrosis factor alpha in cerebrospinal fluid
change of tumor necrosis factor alpha levels in cerebrospinal fluid compared to baseline
Time frame: 12 months
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification (text, tables, and figures) as well as the study protocol will be available.
Supporting information: Study protocol
Time frame: Data will be available beginning 3 months and ending 5 years following article publication.
Access criteria: Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal.
Data sharing details ↗ · www.uniklinik-ulm.de
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Apr 2028, 45 months after the start.
Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 45 months is above that.
Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jun 2024 → Jul 2024, primary completion Jan 2028 → Apr 2028 and completion Jan 2028 → Apr 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →